Reunion Sues Psychedelics Rival Mindset Over ‘Reneged’ Handshake

Reunion Neuroscience Inc. alleges that Mindset Pharma Inc. used the public disclosure of its patented psychedelic treatment for post-partum depression to claim the same compound in Mindset’s own patent, threatened to sue, and reneged on a licensing deal, damaging Reunion’s ability to secure funding.

Toronto-based Reunion says its chief scientific officer, Nathan Bryson, conceived of RE-104—"a serotonergic psychedelic therapy that directly agonizes the serotonin receptor”—and that the inventors listed on a patent issued to Mindset Feb. 28 “did not conceive that compound.”

“Instead, Mindset only included Reunion’s RE-104 compound structure in its patent application after the publication of Reunion’s application ...